2026-08-10 · BOTH · TopGLP1Providers Data Desk

Needle-free GLP-1s: what the pill and the tablets cost, and what only one of them has proven

Going needle-free now has two very different paths. The FDA-approved path is oral Wegovy, launched January 2026 at $149–$299 a month cash through NovoCare↗ depending on dose — an approved tablet with trial data behind it. The compounded path is sublingual tirzepatide or semaglutide (dissolving tablets or drops): NexLife↗ prices tirzepatide ODT at $229 a month ($199 on a prepaid year) and semaglutide ODT at $199; Henry's sublingual semaglutide runs about $179. The decisive difference is not price — it is that oral absorption of these peptides is hard, the approved pill solved it with a specific absorption-enhancer technology, and compounded sublingual products have published no equivalent human evidence.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

The pharmacology in one paragraph: swallowed peptides get shredded by digestion, which is why these drugs launched as injections. Novo's approved oral semaglutide works by co-formulating with an absorption enhancer (SNAC) and still delivers only a small fraction of the swallowed dose — a fraction characterized in trials, which is what makes dosing rational. Compounded sublingual products aim to bypass the gut through the oral mucosa instead; the concept is plausible, the human bioavailability data for these specific peptides by that route is essentially absent from the literature. That does not mean nothing is absorbed. It means nobody can tell you, with evidence, how much — which turns dosing from measurement into hope.

Priced as products anyway, because they are sold as products: within the compounded index, ODT tiers carry a premium over the same provider's injections (NexLife's tirzepatide ODT at $229 versus its $215 injection; semaglutide ODT $199 versus $165), which prices the needle-avoidance at roughly $14–$34 a month. Meanwhile the approved pill at $149–$299 sits below most compounded sublingual tiers. Our rankings therefore keep ODT products in their own lane — they never compete against injectables in the cheapest-provider indexes — and our editorial line is blunt: if needles are the obstacle, the burden of proof sits with any option that costs more than the approved pill while publishing less evidence than it. If a prescriber has a specific reason a compounded sublingual fits your case, that reasoning — not the marketing page — is the thing to write down.

Absorption and formulation questions are clinical ones; take them to a prescriber or pharmacist, not a checkout page.